# **Supplementary Materials for: Virtual Exam for Parkinson's Disease Enables Frequent and Reliable Measurements of Motor Function**

Maximilien Burq<sup>1</sup>, Erin Rainaldi<sup>1</sup>, King Chung Ho<sup>1</sup>, Chen Chen<sup>1</sup>, Bastiaan R. Bloem<sup>2</sup>, Luc Evers<sup>2</sup>, Rick C. Helmich<sup>2</sup>, Lance Myers<sup>1</sup>, William Marks<sup>1</sup>, Ritu Kapur<sup>1</sup>

## **Supplementary Methods: Description of the hardware platform**

All sensor data collection in this study used a wrist-worn wearable device, the 2nd-generation of the Verily Study Watch. It features an inertial measurement unit (IMU) (3-axis accelerometer with range  $+/-$  16 G; and 3-axis gyroscope with range  $+/-$  2000 DPS), photoplethysmography, electrocardiogram (ECG), and electrodermal activity sensors, and several environmental sensors. In this study, the IMU is sampled at 100 Hz, except during a MDS-UPDRS or PD-VME exam, during which it is sampled at 200 Hz.

## **Participant-facing instructions for the PD-VME.**





**Supplementary Table 1.** Participant-facing instructions for the VME.

### **Engagement**



**Supplementary Figure 1, Engagement: (A)** Study Watch median daily wear time (hours) by day of study across the whole PPP cohort. The grey shaded area represents the 25th and 75th percentiles of wear time for a given day. The median wear time is 22.1 hours per day. The number of participants used to compute the median wear time decreases with the increase of "time since start", because a proportion of participants have been enrolled <3 years ago and are still actively contributing data. **(B)** Percentage of participants in set 2 with at least one PD-VME per week.



**Supplementary Table 2**. Reasons for dropout of the main PPP study, as of Jan 2022

## **Observations of in-clinic performance of the PD-VME**





\*Focus on either speed or amplitude (rather than both) among all 292 participants: 9.6% (28)

**Supplementary Table 3**. Deviations in the execution of the in-clinic PD-VME, observed by the assessors (percentage followed by number of cases in brackets). For each participant (n=292), only the first in-clinic PD-VME after receiving remote instructions is included. a: missing because the participant did not perform this task during the visit (e.g. due to severe gait impairments in the off state).

#### **Supplementary notes: Tremor**

Three methods for tremor severity algorithms were considered, based on published literature and authors' previous experience with similar wrist-worn devices: lateral tremor acceleration, total tremor acceleration, lateral tremor amplitude. Lateral tremor acceleration is obtained by computing the median absolute tremor acceleration along the lateral axis of the accelerometer signal, after filtering out the gravitational component. This is the axis parallel to 3 and 9 o'clock on the watch face. Total tremor acceleration is obtained similarly, but on the norm of the acceleration vector rather than a single axis.

The final algorithm was selected based on correlations with the in-clinic MDS-UPDRS rest tremor (3.17) single-rater score, for a subset of patients from Set 2 (some of which also belonged to Set 1). For patients who also belonged in Set 1, only clinic visits where consensus scores were not collected were used for algorithm selection.



**Supplementary Table 4.** Rest tremor methods.



**Supplementary Table 5.** Postural tremor methods.

#### **Postural tremor**



**Supplementary Figure 2. Postural tremor acceleration (A)** Lateral tremor acceleration (log scale) measured during the in-clinic examination, separated by postural tremor (MDS-UPDRS 3.15) consensus scores. **(B)** Raw acceleration signals, along the y axis, collected from example participants, are associated with each clinical score. Measurement values, as computed by the PD-VME are also indicated. **(C)** Mean and 95% Confidence interval of at-home lateral tremor acceleration, aggregated over a 2-month baseline period, in two different medication states: On and Off-levodopa. **(D)** User interface providing participant-facing instructions when performing the unsupervised virtual tremor assessment. **(E)** Intra-class correlation between at-home measurements. Whiskers represent 95% confidence intervals. The first column measures week-over-week test-retest reliability of a single measurement. The second column measures the month-over-month test-retest reliability of the monthly-averaged measurements. The third column is similar but with bi-monthly averaging. The dotted blue line and light blue shading represent the published postural tremor test-retest  $\text{ICC}^1$  and the associated 95% confidence interval. **(F)** Distribution of tremor measurements in the Off-medication state, by participant. Participants are ordered according to their median at-home PD-VME measurement. Each vertical blue bar represents the 25th and 75th percentile of at-home measurements for a given participant. Red dots represent the in-clinic sensor measurement obtained during the MDS-UPDRS assessment.

The method to compute postural tremor acceleration was chosen to match the one selected for rest tremor. The rest of the analysis follows the same logic.

The Spearman rank correlation between the log of the median wrist acceleration during the postural tremor task and expert consensus rating of MDS-UPDRS task 3.15 was  $\rho = 0.60$ [0. 49, 0. 69],  $N = 154$  (Fig. 4.A). Change (Cohen's D of 0.19) was observed in the tremor acceleration when comparing before and after levodopa intake. (Fig. 4.C). Week-on-week intra-class correlation (ICC) of  $0.68$  [0.51-0.82] is shown in figure 4.E (N=208). When the measurements are averaged over one month, the month-on-month test-retest ICC increased to  $0.90$   $[0.83 - 0.95]$   $(N=139)$ .

#### **Supplementary Methods: Bradykinesia**

The PD-VME task to measure bradykinesia resembles the MDS-UPDRS 3.6 pronation-supination task: participants are asked to twist their arms, hands extended, as widely as possible, for a duration of 20 seconds.

Two methods were considered for bradykinesia estimation: arm twist amplitude (in degrees), and arm rotational speed (in degrees per second).<sup>2</sup> For both methods, correlation against the in-clinic MDS-UPDRS pronation-supination (3.6) single-rater score was similar, and arm twist amplitude was selected. Arm twist amplitude was computed along the x-axis of the gyroscope sensor on Study Watch by integrating the signal using polynomial detrending and taking the median value.

To more precisely detect the start and end of the task, a segmentation method was applied by selecting the first and last times where the gyroscope signal exceeds a given threshold. Thresholds were selected out of a total of 6 combinations, based on the correlation to single-rater MDS-UPDRS scores.





**Supplementary Table 6.** Bradykinesia methods.

#### **Supplementary methods: Gait**

The PD-VME task for gait task resembles a combination of the MDS-UPDRS 3.9 sit-to-stand and 3.10 gait tasks. Participants are instructed to get up from a chair, with arms crossed over their chest, and walk back and forth for a duration of 60 seconds.

Several methods<sup>3-5</sup>were considered to quantify gait impairment symptoms. The arm swing amplitude<sup>5</sup> was explored owing to high correlation with single-rater MDS-UPDRS  $3.10$ ratings, and its published ability to capture disease progression, and act as a prodromal marker of PD $^{6-8}$  Arm swing acceleration captures the maximum range of vertical acceleration of a PD patient while they are walking. It is defined as the norm of the x-axis and y-axis accelerations. Additionally, arm swing forward acceleration was calculated and compared. This feature captures the load changes of the wrist acceleration from the repetitive impacts from steps during walking. It is defined as the rate of change of forward acceleration (x-axis) during walking.<sup>3</sup> Spectral features extracted from the power spectral density (PSD) within the walking frequency  $(\leq 2.5 \text{ Hz})$  were also explored. These features are the peak frequency in the PSD and the corresponding peak magnitude. Peak frequency is defined as the cadence (i.e., the walking speed) during the MDS-UPDRS walking task. The peak arm swing energy was also calculated, which is defined as the peak magnitude within the walking frequency  $(\leq 2.5 \text{ Hz})$  in the power spectral density (PSD).



acceleration

**Supplementary Table 7.** Gait methods.

## **Supplementary References**

- 1. Siderowf A, [McDermott](http://paperpile.com/b/2AUwrk/I0gA) M, Kieburtz K, Blindauer K, Plumb S, Shoulson I. Test-retest reliability of the unified [Parkinson's](http://paperpile.com/b/2AUwrk/I0gA) disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. *Mov Disord*. [2002;17\(4\).](http://paperpile.com/b/2AUwrk/I0gA) doi:[10.1002/mds.10011](http://dx.doi.org/10.1002/mds.10011)
- 2. Mahadevan N, Demanuele C, Zhang H, et al. [Development](http://paperpile.com/b/2AUwrk/7Ewl) of digital biomarkers for resting tremor and [bradykinesia](http://paperpile.com/b/2AUwrk/7Ewl) using a wrist-worn wearable device. *npj Digital Medicine*. 2020;3(1). [doi:](http://paperpile.com/b/2AUwrk/7Ewl)[10.1038/s41746-019-0217-7](http://dx.doi.org/10.1038/s41746-019-0217-7)
- 3. Soltani A, Dejnabadi H, Savary M, Aminian K. [Real-World](http://paperpile.com/b/2AUwrk/t5Cy) Gait Speed Estimation Using Wrist Sensor: A [Personalized](http://paperpile.com/b/2AUwrk/t5Cy) Approach. *IEEE Journal of Biomedical and Health Informatics*. [2020;24\(3\):658-668.](http://paperpile.com/b/2AUwrk/t5Cy) doi:[10.1109/jbhi.2019.2914940](http://dx.doi.org/10.1109/jbhi.2019.2914940)
- 4. Zampieri C, Salarian A, [Carlson-Kuhta](http://paperpile.com/b/2AUwrk/4V4p) P, Aminian K, Nutt JG, Horak FB. The instrumented timed up and go test: potential outcome measure for disease modifying therapies in [Parkinson's](http://paperpile.com/b/2AUwrk/4V4p) disease. *J Neurol Neurosurg Psychiatry*. [2010;81\(2\).](http://paperpile.com/b/2AUwrk/4V4p) doi[:10.1136/jnnp.2009.173740](http://dx.doi.org/10.1136/jnnp.2009.173740)
- 5. Horak FB, Mancini M, [Carlson-Kuhta](http://paperpile.com/b/2AUwrk/ZxDN) P, Nutt JG, Salarian A. Balance and Gait Represent [Independent](http://paperpile.com/b/2AUwrk/ZxDN) Domains of Mobility in Parkinson Disease. *Physical Therapy*. [2016;96\(9\):1364-1371.](http://paperpile.com/b/2AUwrk/ZxDN) doi:[10.2522/ptj.20150580](http://dx.doi.org/10.2522/ptj.20150580)
- 6. Din SD, Del Din S, Elshehabi M, et al. Gait analysis with wearables predicts [conversion](http://paperpile.com/b/2AUwrk/CibX) to Parkinson disease. *Annals of Neurology*. [2019;86\(3\):357-367.](http://paperpile.com/b/2AUwrk/CibX) doi:[10.1002/ana.25548](http://dx.doi.org/10.1002/ana.25548)
- 7. Mirelman A, [Bernad-Elazari](http://paperpile.com/b/2AUwrk/VGH2) H, Thaler A, et al. Arm swing as a potential new prodromal marker of Parkinson's disease. *Movement Disorders*. [2016;31\(10\):1527-1534.](http://paperpile.com/b/2AUwrk/VGH2) doi[:10.1002/mds.26720](http://dx.doi.org/10.1002/mds.26720)
- 8. [Probabilistic](http://paperpile.com/b/2AUwrk/x5BB) Modelling of Gait for Robust Passive Monitoring in Daily Life. Accessed July 9, [2021.](http://paperpile.com/b/2AUwrk/x5BB) <https://doi.org/10.1109/jbhi.2020.3037857>